Detalhe da pesquisa
1.
ctDNA improves prognostic prediction in relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.
Blood
; 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38427753
2.
The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin-transferrin receptor 1 axis.
Blood
; 142(4): 352-364, 2023 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37146246
3.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Blood
; 139(6): 835-844, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289038
4.
Nomogram for predicting survival of patients with diffuse large B-cell lymphoma.
Ann Hematol
; 103(6): 2041-2050, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38411628
5.
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.
Ann Hematol
; 103(2): 475-488, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37695378
6.
Fulminant hepatitis in a hepatitis B surface antigen-positive patient with adult T-cell leukemia-lymphoma after mogamulizumab monotherapy.
Hepatol Res
; 2024 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38770705
7.
Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs.
Haematologica
; 108(12): 3399-3408, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37470160
8.
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients.
Hematol Oncol
; 41(3): 424-433, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36426594
9.
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
Hematol Oncol
; 41(3): 442-452, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36433829
10.
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
Ann Hematol
; 102(4): 863-876, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36862168
11.
Clinicopathological significance of CD28 overexpression in adult T-cell leukemia/lymphoma.
Cancer Sci
; 113(1): 349-361, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34738707
12.
Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia.
Cancer Sci
; 113(6): 2085-2096, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35332633
13.
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
Cancer Sci
; 113(12): 4267-4276, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36052883
14.
Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
Br J Haematol
; 196(3): 629-638, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34632569
15.
Feed-forward regulatory loop driven by IRF4 and NF-κB in adult T-cell leukemia/lymphoma.
Blood
; 135(12): 934-947, 2020 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31972002
16.
Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.
Haematologica
; 107(10): 2418-2431, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35417939
17.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Haematologica
; 107(10): 2408-2417, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354247
18.
CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
Hematol Oncol
; 40(5): 876-884, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36043457
19.
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.
Ann Hematol
; 101(10): 2123-2137, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35943588
20.
Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core-related antigen assay.
Hepatol Res
; 52(9): 745-753, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35199427